SETD7 exacerbates diabetic nephropathy through activating A_2B receptor-JAK2/STAT3 pathway

Area of Science:

• Nephrology
• Epigenetics
• Molecular Biology

Background:

• Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD).
• Epigenetic mechanisms are increasingly recognized for their role in DN pathogenesis.
• SET domain-containing lysine methyltransferase 7 (SETD7) is a potential epigenetic regulator in DN.

Purpose of the Study:

• To elucidate the mechanism by which SETD7 influences DN progression.
• To investigate the role of SETD7 in high glucose-induced mesangial cell activation and kidney injury.

Main Methods:

• Utilized SETD7 knockout mice and wild-type controls induced with Streptozocin (STZ) for DN.
• Employed high glucose stimulation in vitro on mouse mesangial cells (SV40-MES-13).
• Analyzed gene expression, protein interactions, and signaling pathway activation (JAK2/STAT3).

Main Results:

• SETD7 expression is upregulated in high glucose conditions and diabetic kidneys.
• SETD7 promotes adenosine A2B receptor (A2BR) transcription, activating JAK2/STAT3 signaling.
• SETD7 deficiency ameliorates renal injury, fibrosis, and inflammation in DN models.

Conclusions:

• SETD7 drives DN progression via the A2BR-mediated JAK2/STAT3 pathway, promoting fibrosis and inflammation.
• Targeting SETD7 presents a promising therapeutic avenue for halting DN progression.